AI-generated content for informational purposes only. Not financial advice. Always do your own research.

关于

Global leader in cloud-connected medical devices for sleep apnea and respiratory care, treating over 160 million patients. Software-driven digital health platform.

老龄化人口股票

ResMed是云连接睡眠呼吸暂停和呼吸护理设备的全球领导者,治疗超过1.6亿患者,并受益于老龄化人口驱动的呼吸治疗需求增长。

Key Financials RMD

价格 $252.55
变化(1天) +2.78%
变化 (30D) +4.85%
变化 (60D) +3.20%
变化 (90D) -10.25%
变化 (180D) +3.18%
变化 (1Y) +6.74%
变化 (5Y) +26.36%
P/E比率 32.09
EPS (TTM) $7.87
52周区间 $199.92 — $293.81
50日MA $252.89
成交量 971.0K

Data updated Feb 15 · Source: Twelve Data

4.3
1 reviews
Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Claude Opus 4.6
AI Review
4.3/5

ResMed is a global leader in sleep apnea and respiratory care devices, positioning it squarely as a beneficiary of aging population demographics. As the elderly population grows, demand for CPAP devices, ventilators, and connected health solutions should expand meaningfully over the coming decades.

Financially, ResMed trades at a P/E of 32x with EPS of $7.87, reflecting a premium valuation justified by its dominant market position and recurring revenue from masks and accessories. The stock sits near its 50-day moving average at ~$253, well off its 52-week high of $294, suggesting potential upside if sentiment improves.

Bull case: Massive underpenetrated sleep apnea market, strong recurring revenue model, digital health integration through myAir and AirView platforms, and demographic tailwinds from aging populations globally. Bear case: GLP-1 weight-loss drugs (Ozempic/Wegovy) could reduce sleep apnea prevalence, competitive pressure from Philips' market re-entry, and the premium valuation leaves limited margin for error. The 90-day decline of -10.25% likely reflects lingering GLP-1 concerns. Despite this overhang, ResMed's fundamentals and demographic positioning remain compelling for long-term investors.

Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Feb 15, 2026
ResMed Screenshot

Added: Feb 15, 2026

resmed.com